BSL3 Enhancements for RNA Virus Pandemic Preparedness

项目概要/摘要 马萨诸塞州陈医学院（UMass Chan）寻求NIH G20资助修复， 更新和现代化现有的生物安全3级（BSL 3）和动物BSL 3（ABSL 3）设施， 目前对可能导致大流行的RNA病毒的研究。作为国际公认的传染病领域的领导者， 疾病研究，马萨诸塞大学陈作出了关键贡献，这一领域，包括工作的严重急性 呼吸道综合征冠状病毒2型，高致病性禽流感病毒，纽卡斯尔病 寨卡病毒是什么？在2019冠状病毒病（COVID-19）大流行开始时，我们迅速成为 在SARS-CoV-2的研究和临床试验方面处于领先地位。我们的研究人员获得了多个奖项， 美国国立卫生研究院，国家科学基金会，国防部，以及这些研究的私人基金会。作为领先的网站， COVID-19临床试验，马萨诸塞大学陈是唯一准备桥梁临床和基础研究研究，这些 通过对患者样本进行必要的研究，以补充体外和体内研究。我们 研究结果可以转化为开发新的预防和治疗策略， RNA治疗研究所，我们的耐药性研究所，以及我们与MassBiologics的疫苗合作伙伴关系 发展，使马萨诸塞大学陈一个发电站的板凳到床边的转化研究。 麻省大学陈BSL 3核心实验室的使用量因疫情而大幅增加。 我们的BSL 3和ABSL 3设施需要进行重大更新和翻新，以跟上我们的研究计划 并继续为BSL 3工作提供安全、现代化和高效的实验室。上次这些设施 十多年前进行了全面翻修（2003 - 2005年为我们的ABLS 3，2010 - 2014年为我们的BSL 3）。我们 将通过更新天花板和通风系统，安装 新的高压灭菌器，通过拆除过时的设备最大限度地提高现有的足迹，并更新摄像机， 安全为代价的这些更新将通过解决以下问题，大大加强对具有大流行潜力的RNA病毒的研究： 这些缺陷导致维修停机时间延长，并通过提高关键 建筑系统。我们的马萨诸塞大学陈设施和校园服务团队有丰富的经验，执行 设计，翻新和监督的运作，并已与美国国立卫生研究院在以前的G20和C06- 资助我们的设施改进。20国集团的资金还将得到强有力的机构支持， 这个项目和承诺，以充分装备最先进的科学仪器， 维持目前资助的SARS-CoV-2研究和未来研究的生产力所需的其他设备 和其他BSL 3水平的RNA病毒病原体。有了G20的资助，我们的BSL 3和ABSL 3实验室可以获得更多- 需要更新，以支持我们的教师，因为他们继续作出突破性的基本发现， 翻译潜力，以解决SARS-CoV-2和其他RNA病毒的流行潜力。

Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH G20 funding to repair, renovate, and modernize the existing Biosafety Level 3 (BSL3) and Animal BSL3 (ABSL3) facilities to enhance current research on RNA viruses of pandemic potential. As an internationally recognized leader in infectious disease research, UMass Chan has made pivotal contributions to this field, including work on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), highly pathogenic avian influenza virus, Newcastle disease virus, and Zika virus. At the start of the coronavirus 2019 (COVID-19) pandemic, we quickly became one of the leading institutes for research and clinical trials on SARS-CoV-2. Our researchers obtained several awards from the NIH, NSF, and Department of Defense, as well as private foundations for these studies. As a leading site for COVID-19 clinical trials, UMass Chan is uniquely poised to bridge clinical and basic research studies on these RNA viruses by enabling essential research on patient samples to complement in vitro and in vivo studies. Our findings can be translated to develop novel prevention and therapeutic strategies leveraging our world-renowned RNA Therapeutics Institute, our Institute for Drug Resistance, and our partnership with MassBiologics for vaccine development, making UMass Chan a powerhouse for bench-to-bedside translational research. The UMass Chan BSL3 Core Laboratories have seen a staggering increase in usage due to the pandemic. Our BSL3 and ABSL3 facilities need major updates and renovations to keep pace with our research programs and continue to provide a safe, modern, and efficient lab for BSL3 work. The last time these facilities were completely renovated was over a decade ago (2003–2005 for our ABLS3 and 2010–2014 for our BSL3). We will modernize the existing BSL3 and ABSL3 facilities by updating the ceiling and ventilation systems, installing new autoclaves, maximizing the existing footprint by removing outdated equipment, and updating cameras for safety. These updates will significantly enhance research on RNA viruses of pandemic potential by addressing deficiencies that have caused prolonged downtime for repairs, and by enhancing the resilience of critical building systems. Our UMass Chan Facilities and Campus Services team has extensive experience executing design, renovations, and oversight of the operations and have worked with the NIH on previous G20 and C06- funded improvements to our facilities. The G20 funding will also be backed by strong institutional support for this project and a commitment to fully equip the updated space with state-of-the-art scientific instruments and other equipment needed to maintain the productivity of currently funded and future research on SARS-CoV-2 and other BSL3-level RNA viral pathogens. With G20 funding, our BSL3 and ABSL3 labs can get much- needed updates to support our faculty as they continue to make ground-breaking fundamental discoveries with translational potential to address SARS-CoV-2 and other RNA viruses of pandemic potential.